Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest

Oculis Holding AG (NASDAQ:OCS) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 316,332 shares, an increase of 212.7% from the December 15th total of 101,167 shares. Based on an average daily trading volume, of 114,783 shares, the days-to-cover ratio is currently 2.8 days. Currently, 0.6% of the company’s shares are sold short. Currently, 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 114,783 shares, the days-to-cover ratio is currently 2.8 days.

Institutional Trading of Oculis

Institutional investors have recently added to or reduced their stakes in the business. Compagnie Lombard Odier SCmA lifted its position in shares of Oculis by 11.5% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after buying an additional 10,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the period. Marshall Wace LLP acquired a new position in Oculis in the second quarter valued at approximately $393,000. Bosun Asset Management LLC bought a new position in shares of Oculis during the second quarter valued at approximately $378,000. Finally, Bank of America Corp DE raised its position in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. Institutional investors own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright raised their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and issued a $51.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Lifesci Capital started coverage on Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. Finally, Bank of America decreased their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and an average target price of $41.50.

Oculis Stock Up 1.0%

Shares of OCS traded up $0.25 during trading on Thursday, reaching $23.91. The company’s stock had a trading volume of 20,497 shares, compared to its average volume of 204,599. Oculis has a twelve month low of $14.00 and a twelve month high of $24.50. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -9.49 and a beta of 0.31. The company has a fifty day moving average of $20.15 and a two-hundred day moving average of $19.05.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, sell-side analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.